Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.

Research in genetics and biotechnology has advanced by leaps and bounds in recent years, offering new hope for the treatment ...

Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.A novel ...